logo-loader

Invex Therapeutics Ltd

Receive alerts
Market:
ASX
Market Cap:
$60.78 m
Price
1.11 AUD
Change
7.28%
52 weeks high
1.69
52 weeks low
0.52

In brief

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.